DK1594517T3 - Sammensætninger til behandlingen af gastrointestinale lidelser - Google Patents

Sammensætninger til behandlingen af gastrointestinale lidelser

Info

Publication number
DK1594517T3
DK1594517T3 DK04706011T DK04706011T DK1594517T3 DK 1594517 T3 DK1594517 T3 DK 1594517T3 DK 04706011 T DK04706011 T DK 04706011T DK 04706011 T DK04706011 T DK 04706011T DK 1594517 T3 DK1594517 T3 DK 1594517T3
Authority
DK
Denmark
Prior art keywords
disorders
constipation
conditions
dyspepsia
functional
Prior art date
Application number
DK04706011T
Other languages
English (en)
Inventor
Mark G Currie
Shalina Mahajan-Miklos
G Todd Milne
Thea Norman
Original Assignee
Microbia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32854294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1594517(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Microbia Inc filed Critical Microbia Inc
Application granted granted Critical
Publication of DK1594517T3 publication Critical patent/DK1594517T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
DK04706011T 2003-01-28 2004-01-28 Sammensætninger til behandlingen af gastrointestinale lidelser DK1594517T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44309803P 2003-01-28 2003-01-28
US47128803P 2003-05-15 2003-05-15
US51946003P 2003-11-12 2003-11-12
PCT/US2004/002390 WO2004069165A2 (en) 2003-01-28 2004-01-28 Methods and compositions for the treatment of gastrointestinal disorders

Publications (1)

Publication Number Publication Date
DK1594517T3 true DK1594517T3 (da) 2007-10-29

Family

ID=32854294

Family Applications (3)

Application Number Title Priority Date Filing Date
DK04706011T DK1594517T3 (da) 2003-01-28 2004-01-28 Sammensætninger til behandlingen af gastrointestinale lidelser
DK07011869.0T DK1911763T3 (da) 2003-01-28 2004-01-28 Sammensætninger til behandling af mavetarmsygdomme
DK10170038.3T DK2246360T3 (da) 2003-01-28 2004-01-28 Sammensætninger til behandlingen af gastrointestinale lidelser

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK07011869.0T DK1911763T3 (da) 2003-01-28 2004-01-28 Sammensætninger til behandling af mavetarmsygdomme
DK10170038.3T DK2246360T3 (da) 2003-01-28 2004-01-28 Sammensætninger til behandlingen af gastrointestinale lidelser

Country Status (29)

Country Link
US (3) US20040266989A1 (da)
EP (3) EP1594517B1 (da)
JP (3) JP4584911B2 (da)
KR (2) KR101227626B1 (da)
CN (2) CN100589839C (da)
AT (2) ATE477268T1 (da)
AU (2) AU2004210161B2 (da)
BE (1) BE2013C032I2 (da)
BR (2) BR122018074353B8 (da)
CA (1) CA2514507C (da)
CY (5) CY1110905T1 (da)
DE (2) DE602004007105T2 (da)
DK (3) DK1594517T3 (da)
ES (3) ES2285417T3 (da)
FR (2) FR13C0029I2 (da)
HK (1) HK1078768A1 (da)
HU (1) HUS1300022I1 (da)
IL (2) IL169863A (da)
LT (1) LTC1594517I2 (da)
LU (2) LU92200I2 (da)
MX (1) MXPA05008097A (da)
NL (1) NL300593I2 (da)
NO (2) NO334112B1 (da)
NZ (2) NZ570134A (da)
PT (3) PT2246360E (da)
RU (2) RU2543350C2 (da)
SG (2) SG168407A1 (da)
SI (3) SI2246360T1 (da)
WO (1) WO2004069165A2 (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2795396C (en) 2001-03-29 2015-11-17 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for stimulating water transport in the gastrointestinal tract to treat tissue inflammation
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
SG168407A1 (en) * 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
PT1644021E (pt) * 2003-06-13 2013-01-30 Ironwood Pharmaceuticals Inc Métodos e composições para o tratamento de distúrbios gastrointestinais
US20050266028A1 (en) * 2004-05-25 2005-12-01 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating an immune response
WO2006046746A1 (ja) * 2004-10-26 2006-05-04 Ajinomoto Co., Inc. 内臓痛予防・治療剤
CA2619650A1 (en) * 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PL1937262T3 (pl) 2005-09-29 2019-10-31 Ipsen Pharma Kompozycja do stosowania w leczeniu zaburzeń motoryki przewodu pokarmowego
US20090305993A1 (en) * 2006-02-24 2009-12-10 Ironwood Pharmaceuticals, Inc. Methods and composition for the treatment of gastrointestinal disorders
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
EP2152266A4 (en) * 2007-05-04 2010-07-28 Ironwood Pharmaceuticals Inc COMPOSITIONS AND METHODS OF TREATING DISORDERS RELATED TO SALT OR LIQUID RETENTION
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US8969514B2 (en) * 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2296685B1 (en) 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110306125A1 (en) * 2008-06-30 2011-12-15 Ironwood Pharmaceuticals, Inc. Protein Expression Methods
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
PE20151205A1 (es) * 2008-08-15 2015-08-31 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral
CA2743172A1 (en) 2008-11-19 2010-05-27 Forest Laboratories Holdings Limited Crystalline form of linaclotide
AU2009322285B2 (en) * 2008-12-03 2016-07-28 Bausch Health Ireland Limited Formulations of guanylate cyclase C agonists and methods of use
WO2010115916A1 (en) 2009-04-10 2010-10-14 F. Hoffmann-La Roche Ag Process for isolating therapeutic peptide
WO2011017502A2 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
EP2464373A1 (en) * 2009-08-13 2012-06-20 Ironwood Pharmaceuticals, Inc. Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists
US20140179607A9 (en) * 2009-11-09 2014-06-26 Ironwood Pharmaceuticals, Inc Treatments for Gastrointestinal Disorders
KR20120103689A (ko) * 2009-12-07 2012-09-19 아이언우드 파마슈티컬스, 인코포레이티드 위장 장애의 치료
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US8748575B2 (en) * 2010-06-09 2014-06-10 Combimab, Inc. Therapeutic peptides
EP3626253B8 (en) 2010-08-11 2022-04-20 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
WO2012037380A2 (en) 2010-09-15 2012-03-22 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012155101A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9303066B2 (en) 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170766A1 (en) 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MD480Z (en) * 2011-07-07 2012-09-30 Elvira Andon Method for treating acute ulcerative nonspecific colitis
PL2776055T3 (pl) 2011-08-17 2017-06-30 Ironwood Pharmaceuticals, Inc. Sposoby leczenia zaburzeń żołądkowo-jelitowych
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
RU2528641C2 (ru) * 2012-08-22 2014-09-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных с синдромом диспепсии в сочетании с избыточной массой тела
CN102875655B (zh) * 2012-09-29 2014-12-17 深圳翰宇药业股份有限公司 一种合成利那洛肽的方法
WO2014118180A1 (en) 2013-01-30 2014-08-07 Sandoz Ag Crystalline form of linaclotide
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
KR20220147691A (ko) 2013-08-09 2022-11-03 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
MX2017013928A (es) * 2015-05-01 2018-01-15 Ironwood Pharmaceuticals Inc Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales.
WO2017160938A1 (en) * 2016-03-15 2017-09-21 The Regents Of The University Of California METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH α8β1 INTEGRIN
CN107929718A (zh) * 2017-10-19 2018-04-20 南京星银药业集团有限公司 Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法
EP3870263A4 (en) * 2018-10-23 2022-08-03 ABK Biomedical Incorporated DISPENSING DEVICE
CN109467606A (zh) * 2018-11-15 2019-03-15 大连理工大学 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
RU2712761C1 (ru) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
CN111265653B (zh) * 2020-02-09 2023-05-09 华中科技大学同济医学院附属协和医院 心房利钠肽在制备炎症性肠病治疗药物中的应用
US20230035733A1 (en) * 2020-03-26 2023-02-02 Dusa Pharmaceuticals, Inc. Management of dermal neurofibromatosis lesions
WO2023144292A1 (en) 2022-01-28 2023-08-03 Fresenius Kabi Ipsum S.R.L. Process for the preparation of linaclotide

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US258687A (en) * 1882-05-30 Grain-binder
US152868A (en) * 1874-07-07 Improvement in type-setting machines
US266989A (en) * 1882-11-07 Automatic fire
US73628A (en) * 1868-01-21 mitchell
US232013A (en) * 1880-09-07 Henry h
US121961A (en) * 1871-12-19 Improvement in devices for supporting pipe-cores
US32684A (en) * 1861-07-02 Stump-extkactob
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
IT1217123B (it) 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (da) 1989-07-28 1992-01-15 Debiopharm Sa
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (fr) 1991-04-02 1994-12-23 Logeais Labor Jacques Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5140102A (en) 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
EP1350799A3 (en) * 1991-12-02 2003-12-03 Millennium Pharmaceuticals, Inc. Inhibitory Immunoglobulin Polypeptides to Human PDGF Beta Receptor
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
CA2151741C (en) 1991-12-30 2001-12-11 Alan Justice Methods of producing analgesia and enhancing opiate analgesia
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
ATE236655T1 (de) 1993-01-06 2003-04-15 Kinerton Ltd Ionische molekularkonjugate von bioabbaubaren polyestern und bioaktiven polypeptiden
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5395490A (en) 1993-05-14 1995-03-07 Intertec, Ltd. Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies
ES2216004T3 (es) * 1993-10-26 2004-10-16 Thomas Jefferson University Composiciones que se unen especificamente a celulas cancerosas colorectales y procedimientos de uso de las mismas.
US5489670A (en) * 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
DK1336409T3 (da) 1995-06-27 2007-08-13 Eisai R&D Man Co Ltd Sammensætninger af formuleringer til fremstilling af analgesimidler og til hæmning af fremadskridende neuropatiske smertelidelser
EP0876347B1 (en) 1995-11-24 2005-03-02 GlaxoSmithKline S.p.A. Quinoline derivatives
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
RU2165942C2 (ru) 1996-04-23 2001-04-27 Кинертон Лимитид Биоразрушаемый сложный полиэфир и способ его получения (варианты)
US6589750B2 (en) 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
AU6823098A (en) 1997-02-28 1998-09-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
JP2001516765A (ja) 1997-09-12 2001-10-02 ヴォルフ ゲオルグ フォースマン 真性糖尿病及び肥満の治療のための組成物
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
IT1304152B1 (it) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
AU6154700A (en) 1999-06-23 2001-01-31 Centre National De La Recherche Scientifique (C.N.R.S.) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
DK1204429T3 (da) 1999-08-18 2004-03-08 Sod Conseils Rech Applic Præparat til forsinket frigivelse af et peptid
SE9903291D0 (sv) 1999-09-15 1999-09-15 Astra Ab New process
WO2001025266A1 (en) 1999-10-06 2001-04-12 Pharmacia Corporation Uroguanylin as an intestinal cancer inhibiting agent
EP1225897B1 (en) 1999-11-01 2004-09-08 RHODES, John Composition for treatment of constipation and irritable bowel syndrome
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
WO2001064212A1 (en) 2000-03-01 2001-09-07 University College London Modulators of the endocannabinoid uptake and of the vallinoid receptors
PT1216707E (pt) 2000-12-22 2005-06-30 Pasteur Institut Novas utilizacoes terapeuticas para um smr-1-peptideo
AU2002235520A1 (en) 2001-02-02 2002-08-19 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
CA2795396C (en) * 2001-03-29 2015-11-17 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for stimulating water transport in the gastrointestinal tract to treat tissue inflammation
EP1451211A2 (en) 2001-03-30 2004-09-01 University of Copenhagen Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
US20050032684A1 (en) * 2001-06-05 2005-02-10 Yalcin Cetin Use of a peptide which activates guanylate-cyclase c for the treatment of respiratory airway problems via the airways, medicament, inhaltion devices and method of diagnosis
FR2830451B1 (fr) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
US20040121961A1 (en) * 2002-02-04 2004-06-24 Jaime Masferrer Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
AU2003224644A1 (en) 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
AU2003225837B2 (en) 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
BR0309969A (pt) 2002-05-17 2005-04-26 Merck Patent Gmbh Uso de compostos que são eficazes como moduladores de receptores seletivos de opiáceos
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US8206704B2 (en) * 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
CA2619650A1 (en) * 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
PT1594517E (pt) 2007-07-20
KR20110114682A (ko) 2011-10-19
ATE365174T1 (de) 2007-07-15
DE602004007105D1 (de) 2007-08-02
LU92201I2 (fr) 2013-11-22
HK1078768A1 (en) 2006-03-24
EP2246360A1 (en) 2010-11-03
AU2009235993B2 (en) 2013-07-04
NO20053864D0 (no) 2005-08-18
FR13C0029I2 (fr) 2024-04-19
JP2013116910A (ja) 2013-06-13
BRPI0407071A (pt) 2006-01-24
NO334112B1 (no) 2013-12-09
BR122018074353B1 (pt) 2019-07-16
PT1911763E (pt) 2010-11-18
PT2246360E (pt) 2012-08-31
NL300593I2 (nl) 2020-04-15
EP2246360B1 (en) 2012-06-27
US20090005534A1 (en) 2009-01-01
WO2004069165A2 (en) 2004-08-19
CY2013022I1 (el) 2020-05-29
US20110124583A1 (en) 2011-05-26
WO2004069165A3 (en) 2005-03-17
JP5563384B2 (ja) 2014-07-30
US20040266989A1 (en) 2004-12-30
AU2004210161B2 (en) 2009-11-26
DE602004028678D1 (de) 2010-09-23
BE2013C032I2 (da) 2023-08-22
NZ541595A (en) 2008-08-29
KR101227627B1 (ko) 2013-01-31
BR122018074353B8 (pt) 2023-05-02
FR13C0029I1 (fr) 2013-07-05
ES2387848T3 (es) 2012-10-02
NL300593I1 (nl) 2015-10-21
ES2350123T3 (es) 2011-01-18
HUS1300022I1 (hu) 2019-11-28
EP1911763B1 (en) 2010-08-11
KR20050106404A (ko) 2005-11-09
CY1111058T1 (el) 2015-06-11
RU2005127058A (ru) 2006-03-10
JP2010222377A (ja) 2010-10-07
NO20053864L (no) 2005-10-26
RU2014153593A (ru) 2016-07-20
LU92200I2 (fr) 2024-03-21
EP1594517A4 (en) 2006-03-29
CY1113217T1 (el) 2016-04-13
BRPI0407071B8 (pt) 2021-05-25
AU2004210161A1 (en) 2004-08-19
NZ570134A (en) 2010-02-26
EP1594517B1 (en) 2007-06-20
RU2543350C2 (ru) 2015-02-27
SG168407A1 (en) 2011-02-28
IL221380A0 (en) 2012-09-24
US8080526B2 (en) 2011-12-20
ATE477268T1 (de) 2010-08-15
KR101227626B1 (ko) 2013-02-01
LU92200I1 (fr) 2020-06-02
US7704947B2 (en) 2010-04-27
CN101787073B (zh) 2013-12-25
EP1594517A2 (en) 2005-11-16
JP4584911B2 (ja) 2010-11-24
NO336768B1 (no) 2015-11-02
CN101787073A (zh) 2010-07-28
CY1110905T1 (el) 2015-06-10
DK2246360T3 (da) 2012-08-13
CN1795007A (zh) 2006-06-28
RU2014153593A3 (da) 2018-08-06
RU2763796C2 (ru) 2022-01-11
FR13C0030I1 (fr) 2013-07-05
EP1911763A3 (en) 2008-06-25
SI1911763T1 (sl) 2010-11-30
JP5748791B2 (ja) 2015-07-15
EP1911763A2 (en) 2008-04-16
BRPI0407071B1 (pt) 2019-02-12
DE602004007105T2 (de) 2008-02-28
RU2353383C2 (ru) 2009-04-27
NO20130460L (no) 2005-10-26
IL169863A (en) 2012-10-31
CN100589839C (zh) 2010-02-17
AU2009235993A1 (en) 2009-11-26
SI1594517T1 (sl) 2007-10-31
LTC1594517I2 (lt) 2020-03-10
DK1911763T3 (da) 2010-11-15
SG192300A1 (en) 2013-08-30
CA2514507C (en) 2012-03-20
JP2006516631A (ja) 2006-07-06
RU2008147983A (ru) 2010-06-10
CA2514507A1 (en) 2004-08-19
CY2013021I1 (el) 2020-05-29
MXPA05008097A (es) 2006-02-08
ES2285417T3 (es) 2007-11-16
SI2246360T1 (sl) 2012-10-30

Similar Documents

Publication Publication Date Title
DK1594517T3 (da) Sammensætninger til behandlingen af gastrointestinale lidelser
SG153824A1 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2007022531A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2005016244A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2006086653A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2007101158A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2008002971A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2005074575A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
EA201290799A1 (ru) Лечение желудочно-кишечных расстройств
WO2007062168A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
CY1113569T1 (el) Μεθοδοι και συνθεσεις για την αγωγη γαστρεντερικων διαταραχων